Overview of Tratomax

What is Tratomax? (Definition and General Purpose)

Property	Description
Active Ingredients	Metronidazole, Nystatin
Form	Vaginal Ovules (Suppositories/Pessaries)
Pharmacological Class	Antiprotozoal, Antibacterial, Antifungal Agent
Common Use	Management of Mixed Vaginal Infections
Origin	Synthetic derivative (Metronidazole) combined with Polyene antibiotic (Nystatin)

Tratomax is a Fixed-Dose Combination (FDC) antimicrobial preparation classified as a dual-action agent for localized treatment. It is a prescription-only medicine (POM) that combines two distinct active ingredients to provide broad-spectrum coverage against common pathogens. The formulation contains Metronidazole, a synthetic nitroimidazole derivative, and Nystatin, which is a polyene antifungal antibiotic. The rationale for combining these two agents is the provision of comprehensive microbial coverage.

Composition and Targeted Action

The medicine’s identity is defined by its two core agents: Metronidazole acts against certain anaerobic bacteria and protozoans, while Nystatin provides essential action against pathogenic fungi. The delivery system is the vaginal ovule form, which is designed for local administration via the vaginal route.

Combination therapies containing both an antiprotozoal/antibacterial component and an antifungal component are utilized for the management of certain complex vaginal infections. This single combined formulation simplifies the treatment and allows for the simultaneous targeting of multiple potential pathogens at the site of infection.

General Purpose and Broad-Spectrum Action

The general purpose of Tratomax is to provide a synergistic effect against microbial causes of general vaginitis. This strategy is intended to address major classes of causative pathogens, thereby promoting the microbial balance for gynecological health. The FDC approach is a defining feature of Tratomax, offering a targeted solution designed for adult women experiencing infections potentially caused by various organisms.

Regulatory References

What side effects are possible with Tratomax?

Possible side effects and safety information

The official safety profile for Tratomax (Metronidazole/Nystatin vaginal ovules) is structured to describe local reactions and potential systemic effects associated with the metronidazole component, as documented by regulatory authorities.

Frequency-Classified Adverse Reactions

The prescribing information classifies adverse effects that occur at the administration site, noting that local reactions like vaginal burning or a gritty sensation are generally considered infrequent and minor. Systemic effects, such as nausea, vomiting, abdominal cramps, and a bitter taste, are also often categorized within the minor frequency bands in the context of this formulation.

Documented Serious Safety Concerns

The regulatory profile documents the potential for rare, serious adverse reactions primarily linked to systemic exposure to metronidazole. These include effects on the Nervous System Disorders class, such as seizures and peripheral neuropathy (tingling or numbness). Furthermore, the risk of Severe Cutaneous Adverse Reactions (SCARs), including Stevens-Johnson Syndrome (SJS), has been noted in official safety materials.

Population-Specific Safety Constraints

The most stringent regulatory restriction involves a contraindication for patients with Cockayne Syndrome due to the reported risk of severe, sometimes fatal, hepatotoxicity. Caution or avoidance is also advised in official labeling during the first trimester of pregnancy and throughout the period of breast-feeding.

Safety-Related Restrictions

Official documents mandate specific limitations on use. Due to the potential for a disulfiram-like reaction, the consumption of alcoholic beverages must be prohibited during therapy and for at least one day afterward. The drug is also contraindicated in patients who have recently taken Disulfiram (within the last two weeks). A known non-pathologic consequence of metronidazole is the darkening of urine.

Overdose and Emergency Response

Overdose Map: Overdose and when to seek help — Official Regulatory Information for Tratomax

This map is compiled from official governmental regulatory documents regarding the overdose profile of Tratomax (Metronidazole/Nystatin), focusing on the systemic effects of the Metronidazole component.

Overdose Scope

Documented overdose presentations: Official documentation lists nausea, vomiting, diarrhea, ataxia, seizures (convulsions), peripheral neuropathy, confusion, and hallucinations.
Physiological systems affected (as stated in label): Gastrointestinal system and Central Nervous System (CNS).
Dose-related or exposure-related factors (if applicable): Manifestations are associated with high systemic absorption or use of excessive doses.
Population-specific overdose notes (if applicable): Exacerbated severity in patients with hepatic impairment (liver dysfunction) is noted in regulatory information concerning systemic Metronidazole exposure.
Emergency-response statements (as written in official documents): Treatment is symptomatic and supportive; hemodialysis may be considered for severe toxicity. No specific antidote is known.
When immediate medical help is required (label-derived phrasing only): Seek immediate medical attention or contact emergency services; hospitalization is required for life-threatening symptoms.

Overdose Classifications (High-Level)

Severity classification (as defined in official documents): Overdose has the potential for severe neurological toxicity (e.g., encephalopathy, cerebellar syndrome).
Regulatory basis (EMA / FDA / etc.): Information is based on government-authorized prescribing information for Metronidazole.
Overdose-context constraints (as defined in official documents): Overdose is primarily considered in the context of high systemic Metronidazole exposure.

Resulting Overdose Structure

Official overdose statements:

Overdose may be characterized by gastrointestinal effects and serious CNS manifestations, including ataxia, seizures, and signs of severe neurological toxicity like encephalopathy.
Seek immediate medical attention or contact emergency services upon suspected overdose due to the risk of severe CNS events; hospitalization may be required for life-threatening symptoms.
No specific antidote is known; overdose management is limited to symptomatic and supportive treatment, with hospital monitoring required to observe for neurological symptoms.

Connection to the Overall Overdose Profile

Regulatory documents define the overdose profile by linking it to the potential for severe neurological toxicity and CNS effects stemming from the Metronidazole component. This necessitates the mandated regulatory action to seek immediate medical attention and underscores the requirement for symptomatic and supportive treatment and monitoring, as no specific antidote is available.

Therapeutic Uses of Tratomax

What Tratomax Treats: Main Uses and Benefits

Tratomax is a combined local treatment commonly used in conditions where symptoms are related to localized infectious processes, focusing solely on therapeutic relief across key symptomatic domains. Its application is directed toward therapeutic contexts involving the management of specific microbial pathogens.

Dual Relief for Mixed Vaginal Infections

This medication is commonly used across conditions characterized by periods of heightened symptoms related to mixed vaginal infections (vaginitis). This often occurs where symptoms may be caused by the co-existence of protozoal/bacterial pathogens and fungal organisms, particularly Candida. It is relevant for managing symptoms in conditions involving fungal, protozoal, or bacterial organisms, such as vaginal candidiasis, trichomoniasis, and bacterial vaginosis. The primary benefit of the combination is that it generally helps to address the co-existence of different microbial causes, which supports the management of acute episodes.

Symptomatic Comfort and Functional Support

Tratomax is applied across domains where additional symptomatic support is needed, addressing symptoms related to inflammatory or irritative states. This includes intense vaginal itching (pruritus), a noticeable burning sensation, and the presence of abnormal discharge and unpleasant odor. Following the management of the underlying conditions, it assists with comfort during periods of heightened symptoms, helping to support general well-being when symptoms are more noticeable and thus contributes to easing the overall symptom load during symptomatic periods.

Quick Fact: Relief for Inflammatory Symptoms The medication is relevant for easing symptoms related to inflammatory or irritative states that interfere with daily comfort or create noticeable functional strain.

Eligibility and Restrictions for Use

Who Can and Cannot Use Tratomax?

This section describes official population eligibility rules for Tratomax (Metronidazole/Nystatin Vaginal Ovules), based strictly on government regulatory documents.

Absolute Regulatory Contraindications

Classification	Who Must Not Use the Medicine
Allergy	Persons with known hypersensitivity to metronidazole, nystatin, imidazole derivatives, or any excipients in the formulation.
Drug Interaction	Patients who have taken Disulfiram within the last two weeks.
Comorbidity	Patients with Cockayne Syndrome.

Conditional Use and Population Restrictions

Population Group	Eligibility Status
Age (Pediatric)	Safety and effectiveness have not been established for children or adolescents (under 18 years).
Pregnancy	Withheld during the first trimester and generally advised to be avoided unless clearly necessary.
Lactation	Exposure should be avoided in nursing women as metronidazole is excreted in human milk.
Organ Function	Use with caution in patients with severe hepatic disease or those with active or chronic severe peripheral/central nervous system diseases.

The official label defines who can and cannot use the medicine by establishing definitive contraindications (absolute exclusions) and specific conditional use requirements based on physiological states or underlying health conditions. The drug is primarily intended for Adult Women.

What should I know about interactions with other medicines?

The interaction profile for Tratomax, a fixed-dose combination, is determined by the systemic exposure of its Metronidazole component, as the Nystatin component has negligible systemic absorption from the vaginal route.

Interaction Category	Interacting Substance	Official Regulatory Restriction and Outcome
Formal Contraindication	Disulfiram	Use is prohibited if Disulfiram was administered within the previous two weeks.
Substance Restriction	Alcoholic Beverages (Ethanol)	Consumption must be avoided during therapy and for at least three days following the final dose due to the documented risk of a disulfiram-like reaction.
Pharmacokinetic Interaction	Warfarin and other oral coumarin anticoagulants	Metronidazole officially potentiates the anticoagulant effect, resulting in a prolongation of prothrombin time.
Exposure Modification	Lithium	Co-administration is associated with a reported elevation of plasma concentrations and potential toxicity.

Restrictions on alcoholic beverages also apply to products containing Propylene Glycol. The official regulatory profile notes that the effects of Metronidazole may be increased in individuals with severe hepatic impairment due to a documented slower clearance of the medicine. Additionally, Metronidazole may interfere with laboratory procedures for determining certain serum chemistry values (such as AST and ALT), potentially causing falsely lowered results. This combination of prohibitions, timing-based requirements, and pharmacokinetic outcome statements defines the product’s official interaction structure.

Mechanism of Action

The mechanism of Tratomax involves two distinct, complementary pathways to induce the termination of microbial cell function directly at the site of application.

The Metronidazole component acts by a unique mechanism dependent on the anaerobic pathogen's internal redox environment. The inactive compound is taken up and then enzymatically reduced by microbial proteins (nitroreductase). This bioactivation generates highly cytotoxic free radicals that irreversibly attack and fragment the pathogen's DNA. This molecular damage rapidly halts replication, resulting in microbial cell death.

Concurrently, the Nystatin component exerts its antifungal effect by a direct physical mechanism. It binds with high affinity to ergosterol, the primary sterol unique to the fungal cell membrane. This binding disrupts structural integrity, leading to the formation of aqueous pores or channels. The resulting physiological consequence is the rapid, uncontrolled leakage of vital intracellular ions and molecules, leading swiftly to fungal cell lysis.

This functional synergy ensures the mechanism simultaneously addresses both the anaerobic/protozoal and fungal pathogen classes, resulting in the localized termination of microbial function across both domains.

Dosage and Administration Information

How to Use Tratomax: Official Administration Guidelines

Tratomax is a fixed-dose combination (FDC) medication intended for administration via the vaginal route only. The medication is formulated as a Vaginal Ovule, with each unit containing 500 mg Metronidazole and 100,000 IU Nystatin. The use of this ovule is strictly local and it is not intended for oral, ophthalmic, or dermal application.

Standard Dosing Regimen

The standard protocol for administration is one vaginal ovule per day. The recommended schedule involves use once daily and specifies administration at bedtime (before retiring) to maximize retention and local exposure.

Procedural Instructions and Course Duration

The full course of treatment requires 10 consecutive days of use. The course is to be completed without interruption, even if the menstrual period begins during the treatment period.

For proper administration, the ovule should be moistened with water for one to two seconds just prior to insertion, and then inserted deeply into the vagina, typically with the aid of the provided applicator. The applicator is not for use after the seventh month of pregnancy. If a dose is missed, the instruction is to skip the forgotten dose and resume the single-dose schedule the following day; a double dose must not be inserted to compensate.

Administration Constraints

The excipients in the ovule can affect the integrity of latex contraceptives, such as condoms and diaphragms, necessitating caution during use. Furthermore, the simultaneous use of other vaginal products, such as douches or tampons, is avoided during the course of treatment.

Recent Clinical Evidence

Tratomax: Recent Clinical Evidence

This overview provides a transparent summary of the clinical research and study landscape for the metronidazole and nystatin combination ovule, focusing on what types of evidence are available and where scientific uncertainty remains, according to official and peer-reviewed sources.

Evidence for Use in Mixed Vaginal Infections

Research has explored the use of the combination ovule in managing conditions characterized by the co-existence of different microbial pathogens, which is consistent with its dual-agent formulation. This evidence is derived primarily from Randomized Controlled Trials (RCTs) and comparative clinical studies. Research examined outcomes related to composite therapeutic cure rates, which are specific measurements combining the resolution of patient-reported symptoms with the assessment of pathogen presence. The evidence often involves comparing this ovule against other existing combination products, and related studies may include formulations with a third active ingredient, which may require careful differentiation.

Evidence for Use in Bacterial Vaginosis (BV)

The evidence base for the use of this combination ovule in Bacterial Vaginosis (BV) includes focused comparative Randomized Controlled Trials (RCTs). These studies monitored whether the condition reappeared by tracking the persistence or recurrence of BV at defined time points after the treatment was finished, using objective laboratory and clinical scoring systems. Findings derived from these settings reported measurements of the patterns observed in recurrence rates when the ovule was compared to single-drug treatments like metronidazole monotherapy.

Evidence for Use in Vaginal Candidiasis and Trichomoniasis

The combination ovule was studied for managing infections caused by C. albicans (candidiasis) and T. vaginalis (trichomoniasis), which is consistent with its dual-component formulation. Research examined outcomes related to mycological eradication and parasite eradication. Data primarily focuses on its use within the context of mixed infections. Comparative evidence is limited when considering its use for an isolated infection against gold-standard monotherapies for that specific condition.

Long-Term Follow-up and Durability of Outcomes

Research has explored short-term symptom changes during treatment and monitored outcomes into the intermediate-term, with some trials observing responses for approximately three to four months. However, long-term effects are not fully established because follow-up durations were limited in many core studies. Consequently, data are still emerging regarding the durability of the observed response.

Evidence in Specific Patient Groups

Studies have monitored outcomes in the core adult women population. Data show patterns related to specific subgroups, such as women using Intrauterine Devices (IUDs). Conversely, data for certain groups remain insufficient. There is limited information available from the core clinical trials regarding its use in post-menopausal women or pregnant and lactating populations.

Understanding Research Gaps and Uncertainty

The research landscape still presents several areas of uncertainty where more data is needed. Comparative evidence is lacking for direct head-to-head comparisons against all currently available alternative combination therapies. Additionally, subgroup findings are uncertain for specific patient profiles outside of the main study groups, and the full scope of long-term outcomes is not yet well characterized.

Key Studies & References

FLAGYSTATIN® (metronidazole and nystatin) Vaginal Ovules Product Monograph

Frequently Asked Questions (FAQ)

Common questions about Tratomax (FAQ)

Q: Is Tratomax the same type of medicine as [similar generic drug name]?

A: Official information defines Tratomax as a fixed-dose combination product. It contains two active ingredients: metronidazole, which is a nitroimidazole antimicrobial, and nystatin, a polyene antifungal agent. This formulation is designed to provide coverage against both types of pathogens.

Q: Can Tratomax affect my sleep schedule?

A: Official regulatory documents list trouble sleeping, medically known as insomnia, as a potential adverse reaction. Any noticeable changes to sleep patterns can be discussed with a healthcare provider.

Q: What are the most common side effects reported with Tratomax?

A: Official product information notes frequently reported effects, including minor local reactions, such as vaginal irritation. Systemic effects like headache, a metallic taste in the mouth, nausea, and vomiting are also often cited.

Q: How long does Tratomax stay in your system?

A: Due to the metronidazole component, the official restriction on alcohol consumption gives an indication of clearance time. Alcoholic beverages are advised to be avoided for at least three days following the final dose, reflecting the time needed for the drug to clear the body sufficiently.

Q: Can Tratomax be taken with food?

A: Tratomax is a vaginal ovule that is administered locally and is not taken by mouth. Therefore, its use is not affected by the timing of food consumption.

Q: Is it normal to feel tired after starting Tratomax?

A: Extreme tiredness or fatigue is not listed among the most frequent adverse reactions. However, official safety profiles note that symptoms such as extreme tiredness have been cited in connection with the medication, sometimes associated with flu-like symptoms.

Q: What is the purpose of the different strengths Tratomax comes in?

A: According to the official product monographs, the fixed-dose combination ovule is documented as only having one strength. This strength contains 500 mg of metronidazole and 100,000 IU of nystatin.

Q: Can Tratomax be crushed or split?

A: Official administration guidelines detail the use of the ovule form, noting it should be moistened and inserted deeply using the provided applicator. These instructions do not provide information or guidance for altering the medication by crushing or splitting it.

Q: Can taking Tratomax affect my mood?

A: Official regulatory warnings note that, in rare cases, the metronidazole component has been associated with central nervous system effects. These effects may include reports of depression, irrational thoughts, and hallucinations.

Q: What is the recommended period of time for treatment with Tratomax?

A: The standard recommended duration for a single course of treatment with this vaginal ovule is 10 consecutive days. The full course is generally described as requiring completion, even if symptoms improve earlier.

Q: Does Tratomax interact with herbal remedies like St. John's Wort?

A: Regulatory documentation indicates there are no known specific drug interactions between metronidazole and common herbal remedies or supplements. However, the guidance suggests reviewing any liquid herbal products to ensure they do not contain alcohol.

Q: Is there a list of all ingredients in Tratomax?

A: Official labeling specifies the active ingredients as metronidazole and nystatin. The complete list of inactive ingredients, known as excipients, is detailed in the full Product Monograph.

Q: Is Tratomax addictive or habit-forming?

A: Tratomax is classified as an antimicrobial agent designed to treat infections. It is not categorized as a narcotic or a controlled substance typically associated with habit-forming potential.

Q: What body systems does Tratomax primarily affect?

A: While the medicine is for localized treatment, there is some systemic exposure to the metronidazole component. Adverse reactions have been officially reported across several body systems, including the gastrointestinal, nervous, and blood/lymphatic systems.

Q: Are there reports of Tratomax causing vision changes?

A: Regulatory safety materials note that transient vision disorders have been reported as potential adverse effects. These effects include, but are not limited to, blurred vision and, in rare instances, optic neuropathy.

Q: Does Tratomax interact with common pain relievers like ibuprofen?

A: Official drug interaction lists specify a formal risk when taking the medicine with Warfarin, Lithium, Disulfiram, and alcohol. Common over-the-counter pain relievers like ibuprofen are not listed as a formal interaction or contraindication in official regulatory labeling.

Q: Is it safe to drink alcohol while taking Tratomax?

A: Regulatory documentation advises that the consumption of alcoholic beverages is to be strictly avoided during therapy and for a minimum of three days after the final dose. This restriction is due to the documented risk of a severe adverse reaction (disulfiram-like effect).

Q: Can I take vitamins or supplements while using Tratomax?

A: Generally, there are no specific restrictions on taking standard vitamins or non-alcohol-containing supplements. However, the official guidance suggests checking the ingredients of any liquid or herbal products to ensure they do not contain alcohol.

Q: What is the difference between the immediate-release and extended-release versions of Tratomax?

A: The official regulatory documents for the metronidazole/nystatin ovule describe only one standard vaginal ovule formulation. Separate immediate-release (IR) or extended-release (ER) forms of this combination product are not referenced in the labeling.

Q: Does Tratomax cause weight gain or weight loss?

A: Weight gain or loss are not listed as common adverse reactions in the safety profile. However, changes in weight are cited as a potential physical symptom of depression, which is a rare, documented nervous system effect.

Q: Are there any long-term effects of taking Tratomax?

A: Current clinical research has limited follow-up duration for the use of this medicine. Therefore, official evidence summaries state that the long-term effects and the durability of the observed treatment outcome are not fully established.

Q: What if I experience unusual dreams or nightmares while on Tratomax?

A: Unusual dreams or nightmares are not specifically classified as common side effects. However, the safety profile does document adverse reactions impacting the nervous system, including trouble sleeping (insomnia) and, rarely, hallucinations.

Q: Can Tratomax interact with caffeine?

A: Official regulatory documentation does not list a specific formal interaction or contraindication between this medicine and caffeine consumption.

Q: What should I know about driving while taking Tratomax?

A: Regulatory guidance notes that this medication may cause side effects like confusion or dizziness. Driving or operating machinery may be avoided if these effects are experienced.

Q: Are there any dietary restrictions mentioned in the official labeling for Tratomax?

A: The official labeling mandates the avoidance of alcoholic beverages and products containing Propylene Glycol during treatment and for a minimum of three days afterward. No other general dietary restrictions concerning food are noted.

Q: What type of research has been done on Tratomax?

A: Clinical evidence is primarily derived from Randomized Controlled Trials (RCTs) and comparative clinical studies. These examine outcomes for mixed vaginal infections, as well as infections caused by bacteria, protozoa, and fungi.

Q: Does Tratomax have different side effects for men versus women?

A: The product is a localized treatment primarily intended for adult women. The listed systemic side effects are related to the metronidazole component, which has a known safety profile regardless of sex, but the drug's use is limited to the female population.

Q: What is the risk of stopping Tratomax suddenly?

A: Official guidance emphasizes that the full course of treatment is generally described as requiring completion without interruption. Completing the full course is generally intended to help resolve the infection completely and may reduce the risk of it returning.

Q: Does Tratomax affect fertility or ability to conceive?

A: Available information on the active component metronidazole indicates there is no clear evidence suggesting that its use reduces fertility in women.

Q: Is Tratomax a narcotic or a controlled substance?

A: Tratomax is classified as an antimicrobial agent, meaning it fights infections. It is not categorized as a narcotic or a controlled substance.

Q: What are the common misunderstandings about how Tratomax works?

A: Clarifications often focus on its identity as a dual-action fixed-dose combination product. Its function is the localized termination of both bacterial/protozoal and fungal cell functions, as opposed to targeting only one type of pathogen.

How should Tratomax be stored and disposed of?

Storage and Handling Requirements

Tratomax (metronidazole/nystatin vaginal ovules) must be stored according to official regulatory labeling to ensure product integrity. The medication requires storage at controlled room temperature, typically defined as 15 C to 25 C (59 F to 77 F).

Protection and Environment: The ovules must be protected from excessive heat, freezing, light, and moisture. Storage in high-humidity areas, such as a bathroom, is prohibited. The product must be kept in its original, closed container to maintain its stability.

Child Safety: All unused product must be kept out of the sight and reach of children and away from pets.

Disposal Instructions

Outdated medicine must not be kept. Disposal of unused or expired Tratomax should follow the instructions of a healthcare professional or pharmacist to ensure compliance with local pharmaceutical waste regulations.

Tratomax